Coeptis Therapeutics Holdings Inc. has received a notice from Nasdaq indicating noncompliance with listing rules due to its failure to hold an annual meeting of shareholders within twelve months of its fiscal year ending December 31, 2024. The company has 45 days from January 12, 2026, to submit a plan to regain compliance, and Nasdaq may grant an extension until June 29, 2026. Coeptis is scheduled to hold its annual meeting on January 30, 2026, which it believes will resolve the compliance issue.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coeptis Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-000370), on January 16, 2026, and is solely responsible for the information contained therein.
Comments